Neuren Pharmaceuticals Limited
NURPF
$10.97
-$1.31-10.67%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 93.85M | 85.79M | 76.66M | 89.99M | 103.69M |
| Total Depreciation and Amortization | 14.50K | 14.50K | 14.40K | 12.80K | 11.30K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.34M | 3.62M | 1.82M | 2.42M | 3.01M |
| Change in Net Operating Assets | -106.60M | -54.20M | -532.90K | 7.31M | 15.10M |
| Cash from Operations | -7.40M | 35.22M | 77.97M | 99.72M | 121.81M |
| Capital Expenditure | -6.60K | -11.50K | -16.40K | -21.40K | -26.60K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.74M | -51.83M | -106.68M | -122.76M | -139.19M |
| Cash from Investing | 2.73M | -51.84M | -106.70M | -122.78M | -139.22M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.66M | 2.93M | 4.19M | 3.92M | 3.64M |
| Repurchase of Common Stock | -10.43M | -5.21M | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -9.00K | -14.50K | -20.00K | -19.00K | -18.00K |
| Cash from Financing | -5.80M | -1.58M | 2.73M | 2.56M | 2.39M |
| Foreign Exchange rate Adjustments | 1.29M | 1.90M | 2.53M | 1.21M | -105.10K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -9.18M | -16.30M | -23.47M | -19.28M | -15.12M |